Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Fate Therapeutics, Inc. Banner

Fate Therapeutics, Inc.

FATE Stock Analysis

Page title

Section title

About Fate Therapeutics, Inc.

Biotechnology
Healthcare

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd...

Fate Therapeutics, Inc. Key Metrics

Market Cap
$442M
52 Weeks Low
$1.63
52 Weeks High
$8.83
P/B
1.15x
P/E
-2.59x
P/S
35.87x

Upcoming Events

    FATE Analyst Forecasts

    ‌
    ‌

    FATE Financials

    FATE Income Statement Key Metrics

    • Revenue(TTM)12.32 M
    • Gross Profit(TTM)-6.85 M
    • EBITDA(TTM)-181.08 M
    • Net Income(TTM)-175.72 M
    • EPS Diluted(TTM)-1.71

    Decode FATE's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    FATE earnings and revenue history

    Gross Profit Margin vs Peers

    Profit margin ratio of FATE (0.712) is higher than the average of its peers (0.202).

    Net Profit Margin vs Peers

    Net profit margin ratio of FATE (-2.533) is higher than the average of its peers (-9.597).

    FATE Return on Equity

    See how efficiently FATE generates profit for it's shareholders.

    -43.68%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of FATE (-0.437) is higher than the average of its peers (-0.828).

    Return on Equity Growth

    FATE's Return on Equity has shown poor growth over the past 10 years, increasing by only -7.11%.

    FATE Revenue Growth

    See how FATE has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    FATE's revenue has grown significantly over the past 10 years, increasing by over 0%.